bifunction

Unleashing bi‑functional
Fusion Proteins

We are creating a new class of fusion proteins through our Agonist Redirected Checkpoint (ARC®) technology.  Solving a fundamental structural limitation of other modalities, ARC molecules target and unlock the TNFr superfamily in a unique fashion while simultaneously blocking an immune checkpoint.

modular

Modular
Technology

Both targets on our dual-sided ARC molecules can be substituted, allowing us to efficiently create thousands of therapeutics and, in turn, address multiple areas of high unmet need.

robust

Robust
Drug Pipeline

Our proprietary portfolio of over 300 bi-functional fusion proteins has been curated to target clinically validated as well as emerging pathways, positioning our therapies to pursue both best-in-class and first-in-class approaches.